Eli Lilly Just Announced More Good News: Time to Buy?

There's no stopping this high-flying biotech.The pharmaceutical business is a tricky one. Developing novel therapies costs hundreds of thousands of dollars, sometimes more. Many never make it to the market despite substantial sums invested by drugmakers. Many of those that do earn approval end up falling short of sales expectations. However, occasionally, some drug therapies pay for the money invested in their development several times over.Analysts think that's the kind Eli Lilly (LLY 1.19%) has in tirzepa ...